Kidney's role in hypertension

Minerva Cardioangiologica

Volumn 57, Issue 6, 2009, Pages 743-759

  Lubanski, M S ^a   McCullough, P A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Cardiovascular diseases; Hypertension; Kidney failure, chronic

Indexed keywords

17BETA (3 FURYL) 5BETA ANDROSTANE 3BETA,14BETA,17ALPHA TRIOL; ALDOSTERONE; ALISKIREN; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; MOXONIDINE; OUABAIN; RENIN; SODIUM; TELMISARTAN; THIAZIDE DIURETIC AGENT;

ADRENERGIC SYSTEM; BLOOD VESSEL TONE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DISEASE COURSE; ESSENTIAL HYPERTENSION; HUMAN; HYPERTENSION; KIDNEY DEVELOPMENT; NONHUMAN; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANIMALS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; EXTRACELLULAR FLUID; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; HYPERTENSION, RENOVASCULAR; KIDNEY; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; POLYMORPHISM, GENETIC; RATS; RATS, INBRED DAHL; RATS, INBRED SHR; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SODIUM; SYMPATHETIC NERVOUS SYSTEM;

EID: 77949605757     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Ong KL, Cheung BM, Man YD, Lau CP, Lam KSL. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007;49:69-75.
2. Lenfant C, Chobanian AV, Jones DW, Roccella EJ. National Heart, Lung, and Blood Institute. Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): resetting the hypertension sails. Hypertension 2003;41:1178-9.
3. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-47.
4. Go AS, Chertow GM, Fan D, McCulloch C, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events and hospitalization. N Engl J Med 2004;351:1296-305.
5. National Kidney Foundation. KDOQI clinical practice guidelines. [cited 2009 November 9]. Available at: www.kidney.org/professionals/kdoqi/guidelines. cfm.
6. Muntner P, He J, Cutler JA, Wildman RP, Whelton PK. Trends in blood pressure among children and adolescents. JAMA 2004;291:2107-13.
7. Din-Dzietham R, Liu Y, Bielo MV, Shamsa F. High blood pressure trends in children and adolescents in national surveys from 2002. Circulation 2007;116:1488-96.
8. Mitsnefes M, Ho PL, McEnery PT. Hypertension and progression of chronic renal insufficiency in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). J Am Soc Nephrol 2003;14:2618-22.
9. Tracy RE, Mercante DE, Moncada A, Berenson G. Quantification of hypertensive nephrosclerosis on an objective rational scale of measure in adults and children. Am J Clin Pathol 1986;85:312-8.
10. Assadi F. Effect of microalbuminuria lowering on regression of left ventricular hypertrophy in children and adolescents with essential hypertension. Pediatr Cardiol 2007;28:27-33.
11. Ridao N, Luño J, de Vinuesa SG, Gómez F, Tejedor A, Valderrábano F et al. Prevalence of hypertension in renal disease. Nephrol Dial Transplant 2001;16(Supplement 1):70-3.
12. Agarwal R, Martin A. Correlates of systolic hypertension in patients with chronic kidney disease. Hypertension 2005;46:514-20.
13. Kasper D, Braunwald E, Fauci A, Hauser S, Longo D, Jameson J et al. Harrison's principles of internal medicine. 16th ed. New York, NY: McGraw Hill Publishing Company; 2005. p. 1463-64, 1639-63, 2130-1.
14. Huang CL, Kuo E, Toto RD. WNK kinases and essential hypertension. Curr Opin Nephrol Hypertens 2008;17:133-7.
15. Lev-Ran A, Porta M. Salt and hypertension: a phylogenetic perspective. Diabetes Metab Res Rev 2005;21:118-31.
16. Hsu CY, McCulloch, Darbinian J, Go AS, Iribarren C. Elevated blood pressure and risk of End Stage Renal Disease in subjects without baseline kidney disease. Arch Intern Med 2005;165:923-8.
17. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE et al.; for the AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. Ann Intern Med 2000;139:244-52.
18. Tracy RE. The heterogeneity of vascular findings in the kidneys of patients with benign essential hypertension. Nephro Dial Transplant 1999;14:1634-9.
19. Lurbe E, Redon J, Kesani A, Pascual JM, Tacons J, Alvarez et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 2002;347:797-805.
20. Dahl LK, Heine M. Primary role of renal homografts in setting chronic blood pressure levels in rats. Circ Res1975;36:692-6.
21. Bianchi G, Fox U, Di Francesco GF, Giovanetti AM, Pagetti D. Blood pressure changes produced by kidney cross-transplantation between spontaneously hypertensive rats and normotensive rats. Clin Sci Mol Med 1974;47:435-48.
22. Rettig R, Folberth C, Stauss H, Kopf D, Waldherr R, Unger T. Role of the kidney in primary hypertension: a renal transplantation study in rats. Am J Physiol 1990;258:F606-F11.
23. Strandgaard S, Hansen U. Hypertension in renal allograft recipients may be conveyed by cadaveric kidneys from donors with subarachnoid haemorrhage. BMJ 1986;292:1041-4.
24. Curtis JJ, Luke RG, Dustan HP, Whelchel JD, Jones P, Diethelm AG. Remission of essential hypertension after renal transplantation. N Engl J Med 1983;309:1009-15.
25. van Hooft IMS, Grobbee DE, Derkx FHM, de Leeuw P, Schalekamp MADH, Hofman A. Renal hemodynamics and the renin-angiotensin-aldosterone system in normotensive subjects with hypertensive and normotensive parents. N Engl J Med 1991;324:1305-11.
26. Coffman TM, Crowley SD. Kidney in hypertension - Guyton Redux. Hypertension 2008;51:811-6.
27. Meneton P, Jeunemaitre X, de Wardener H, Macgregor G. Links between dietary salt intake, renal salt handling, blood pressure, and cardiovascular diseases. Physiol Rev 2005;85:679-715.
28. Keller G, Zimmer G, Mall G, Ritz E, Amann K. Nephron number in patients with primary hypertension. N Engl J Med 2003;348:101-8.
29. Zandi-Nejad K, Luyckx V, Brenner B. Adult hypertension and kidney disease: the role of fetal programming. Hypertension 2006;47;502-8.
30. Liew G, Wang J, Duncan B, Klein R, Sharrett AR, Brancati F et al. Low birth weight is associated with narrower arterioles in adults. Hypertension 2008;51:933-8.
31. Kaplan NM. Primary hypertension: pathogenesis. Kaplan's clinical hypertension. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006. p. 50-121.
32. Montani JP, Van Vliet BN. Understanding the contribution of Guyton's large circulatory model to long-term control of arterial pressure. Exp Physiol 2009;94:382-8.
33. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001;344:3-10.
34. Guyton AC. Long-term arterial pressure control: an analysis from animal experiments and computer and graphic models. Am J Physiol Regul Integr Comp Physiol 1990;259:R865-R77.
35. Blaustein MP, Zhang J, Chen L, Hamilton BP. How does salt retention raise blood pressure? Am J Physiol Regul Integr Comp Physiol 2006;290:R514-23.
36. Skov K, Mulvany MJ. Structure of renal afferent arterioles in the pathogenesis of hypertension. Acta Scand 2004;181:397-405.
37. Yu H, Burrell L, Black J, Wu LL, Dilley RJ, Cooper ME et al. Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circulation 1998;98:2621-28.
38. Fujiwara N, Osanai T, Kamada T, Katoh T, Takahashi K, Okumura K. Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension: modulation of nitric oxide synthesis by salt intake. Circulation 2000;101:856-61.
39. Sanders P. Vascular consequences of dietary salt intake. Am J Physiol Renal Physiol 2009;297:F237-F43.
40. Johnson R, Rodriguez-Iturbe B, Nakagawa T. Subtle renal injury is likely a common mechanism for salt-sensitive essential hypertension. Hypertension 2005;45:326-30.
41. Rodriguez-Iturbe B, Vaziri ND, Herrera-Acosta J, Johnson RJ. Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: all for one and one for all. Am J Physiol Renal Physiol 2004;286:F606-F61.
42. Yu H. Progression of chronic renal failure. Arch Intern Med 2003;163:1417-29.
43. Johnson R, Segal M, Srinivas T. Essential hypertension, progressive renal disease, and uric acid: a pathogenic link? J Am Soc Nephrol 2005;16:1909-19.
44. Johnson RJ, Gordon K, Suga S, Griffin K, Bidani A. Renal injury and salt-sensitive hypertension after exposure to catecholamines. Hypertension 1999;34:151-9.
45. Franco M, Tapia E, Santamaria J, Zafra I, Garcia-Torres R, Gordon KL et al. Renal cortical vasoconstriction contributes to development of salt-sensitive hypertension after angiotensin II exposure. J Am Soc Nephrol 2001:12;2263-71.
46. Ballew JR, Fink GD. Role of endothelin ETB receptor activation in angiotensin II-induced hypertension: effects of salt intake. Am J Physiol Heart Circ Physiol 2001;281:H2218-H25.
47. Verhagen AMG, Braam B, Boer P, Grone HJ, Koomans HA, Joles JA. Losartan-sensitive renal damage caused by chronic NOS inhibition does not involve increased renal angiotensin II concentrations. Kidney Int 1999;56:222-31.
48. Henderson NC, Mackinnon AC, Farnworth SL, Kipari T, Haslett C, Iredale JP et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 2008;172:288-98.
49. Fink G. Sympathetic activity, vascular capacitance, and long term regulation of arterial pressure. Hypertension 2009;53:307-12.
50. Desir GV. Regulation of blood pressure and cardiovascular function by renalase. Kidney Int 2009;76:366-70.
51. Campese VM. Neurogenic factors and hypertension in renal failure. Kidney Int 2000;57(Suppl 75):S2-S6.
52. Klein I, Ligtenberg G, Neumann J, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol 2003;14:3239-44.
53. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999;341:577.
54. Katholi RE, Whitlow PL, Hageman GR, Woods WT. Intrarenal adenosine produces hypertension by activating the sympathetic nervous system via the renal nerves in the dog. J Hypertens1984;2:349-59.
55. Faber J, Brody M. Afferent renal nerve dependent hypertension following acute renal artery stenosis in the conscious rat. Cir Res 1985;57:676-88.
56. Erami C, Zhang H, Ho JG, French DM, Faber JE. Alpha(1)-adrenoceptor stimulation directly induces growth of vascular wall in vivo. Am J Physiol Heart Circ Physiol 2002;283:H1577-H87.
57. Kriz W, Gretz N, Lemley KV. Progression of glomerular diseases: Is the podocyte the culprit? Kidney Int 1998;54:687-97.
58. Huber TB, Gloy J, Henger Aet, Schollmeyer P, Greger R, Mundel P, Pavenstadt H. Catecholamines modulate podocyte function. J Am Soc Nephrol 1998;9:335-45.
59. Dhaun N, Goddard J, Kohan D, Pollock DM, Schiffrin EL, Webb DJ. Role of endothelin-1 in clinical hypertension. Hypertension 2008;52:452.
60. Verhaar MC, Strachan FE, Newby DE, Cruden NL, Koomans HA, Rabelink TJ et al. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998;97:752-56.
61. Ahn D, Ge Y, Stricklett P, Gill P, Taylor D, Hughes A et al. Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention. J Clin Invest 2004;114:504-11.
62. Schneider M, Ge Y, Pollock D, Pollock J, Kohan D. Collecting duct-derived endothelin regulates arterial pressure and na excretion via nitric oxide. Hypertension 2008;51:1605.
63. Pollock DM, Pollock JS. Evidence for endothelin involvement in the response to high salt. Am J Physiol Renal Physiol 2001;281:F144-F50.
64. Ge Y, Bagnall A, Stricklett PK, Strait K, Webb DJ, Kotelevtsev Y et al. Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am J Physiol 2006;291:1274-80.
65. Zeidel ML, Brady HR, Kone BC, Gullans SR, Brenner BM. Endothelin, a peptide inhibitor of Na+-K+-ATPase in intact tubular epithelial cells. Am J Physiol Cell Physiol 1989;257:C1101-C7.
66. Stricklett PK, Hughes AK, Kohan DE. Endothelin-1 stimulates NO production and inhibits cAMP accumulation in rat inner medullary collecting duct through independent pathways. Am J Physiol 2006;290:F1315-F9.
67. Orisio S, Benigni A, Bruzzi I, Corna D, Perico N, Zoja C et al. Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int 1993;43:354-8.
68. Goddard J, Johnston NR, Cumming AD, Webb DJ. Fractional urinary excretion of endothelin-1 is reduced by acute ETB receptor blockade. Am J Physiol 2007;293:1433-8.
69. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-6.
70. Kwon O, Hong SM, Ramesh G. Diminished NO generation by injured endothelium and loss of macula densa nNOS may contribute to sustained acute kidney injury after ischemia-reperfusion. Am J Physiol Renal Physiol 2009;296:F25-F33.
71. Matsuguma K, Ueda S, Yamagishi S, Matsumoto Y, Kaneyuki U, Shibata R et al. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. J Am Soc Nephrol 2006;17:2176-83.
72. Shultz PJ, Tolins JP. Adaptation to increased dietary salt intake in the rat. Role of endogenous nitric oxide. J Clin Invest 1993;91:642-50.
73. Ozawa Y, Hayashi K, Kanda T, Homma K, Takamatsu I, Tatematsu S et al. Impaired nitric oxide and endothelium derived hyperpolarizing factor dependent dilation of renal afferent arteriole in Dahl salt sensitive rats. Nephrology 2004;9:272-7.
74. Fujiwara N, Osanai T, Kamada T, Katoh T, Takahashi K, Okumura K. Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension. Circulation 2000;101:856.
75. Leiper J, Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 1999;43:542-8.
76. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-5.
77. Navar LG, Imig JD, Zou L, Wang CT. Intrarenal prod uction of angiotensin II. Semin Nephrol 1997;17:412-22.
78. Gonzalez-Villalobos RA, Satou R, Seth DM, Semprun-Prieto L, Katsurada A, Kobori H et al. Angiotensin Converting Enzyme Derived Angiotensin II Formation During Angiotensin II Induced Hypertension. Hypertension 2009;53:351-5.
79. JE Hall, MW Brands, JR Henegar. Angiotensin II and long-term arterial pressure regulation: the overriding dominance of the kidney. J Am Soc Nephrol 1999;10(Suppl 12):S258-65.
80. Rang YM, Ma Y, Zheng JP, Elks, C, Sriramula S, Yang ZM, Francis J. Brain nuclear factor kappa B activation contributes to neurohumoral excitation in angiotensin II induced hypertension. Cardiovasc Res 2009;82:503-12.
81. Johnson RJ, Alpers CE, Yoshimura A, Lombardi D, Pritzl P, Floege J et al. Renal injury from angiotensin II mediated hypertension. Hypertension 1992;19:464-74.
82. Liao TD, Yang XP, Liu YH, Shesely E, Cavasin MA, Kuziel WA et al. Role of inflammation in the development of renal damage and dysfunction in angiotensin II induced hypertension. Hypertension 2008;52:256-63.
83. Hahn AW, Jonas U, Buhler FR, Resink TJ. Activation of human peripheral mononcytes by angiotensin II. FEBS lett 1994;347:178-80.
84. Vagnes OB, Iversen BM, Arendshorst WJ. Short term angiotensin II produces renal vasoconstriction independent of TP receptor activation and TxA2/isoprostane production. Am J Physiol Renal Physiol 2007;293:F860-7.
85. Ponnuchamy B, Khalil RA. Cellular mediators of renal vascular dysfunction in hypertension. Am J Physiol Renal Physiol 2009;296:R1001-8.
86. Rodriguez-Iturbe B, Johnson RJ. Role of inflammatory cells in the kidney in the induction and maintenance of hypertension. Nephrol Dial Transplant 2006;21:260-63.
87. G Nguyen. Renin/prorenin receptors. Kidney Int 2006;69:1503-6.
88. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006;69:105-13.
89. Mercure C, Prescott G, Lacombe MJ, Silversides DW, Reudelhuber TL. Chronic increases in circulating prorenin are not associated with renal or cardiac pathologies. Hypertension 2009;53:1062-9.
90. Becker GJ, Hewitson TD, Chrysostomou A. Aldosterone in clinical nephrology old hormone, new questions. Nephrol Dial Transplant 2009;24:2316-21.
91. Hatakeyama H, Miyamori I, Fujita T, Takeda Y, Takeda R, Yamamoto H. Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 1994;269:24316-20.
92. Schmidt BMW, Sammer U, Fleischmann I, Schleich M, Delles C, Schmieder R. Rapid nongenomic effects of aldosterone on the renal vasculature in humans. Hypertension 2006;47:650.
93. Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension 2006;47:312-18.
94. Ninomiya T, Kiyohara Y, Tokuda Y, Doi Y, Arima H, Harada A et al. Impact of kidney disease and blood pressure on the development of cardiovascular disease: an overview from the Japan arteriosclerosis longitudinal study. Circulation 2008;118:2694-701.
95. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 1996;27:347-54.
96. Astor B, Hallan S, Miller E, Yeung E, Coresh J. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol 2008;167:1226-34.
97. Elsayed E, Tighiouart H, Griffith J, Kurth T, Levey A, Salem D et al. Cardiovascular disease and subsequent kidney disease. Arch Intern Med 2007;167:1130-6.
98. Appel LJ, Wright JT, Greene T, Kusek JW, Lewis JB, Wang X et al. for the African American Study of Kidney Disease (AASK) and Hypertension Collaborative Research Group. Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med 2008;168:832-9.
99. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J et al. ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-53.
100. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.
101. Gradman A, Kad R. Renin inhibition in hypertension. J Am Coll Cardiol 2008;51:519-28.
102. Mukaddam-Daher S, Menaouar A, Paquette P, Jankowski M, Gutkowska J, Gillis M et al. Hemodynamic and cardiac effects of chronic eprosartan and moxonidine therapy in stroke-prone spontaneously hypertensive rats. Hypertension 2009;53:775-81.